Patents Examined by Stanley J. Friedman
  • Patent number: 5190962
    Abstract: The optically pure isomer of nitrendipine having anti-hypertensive activity, is a potent anti-hypertensive drug for reducing blood pressure in individuals without the undesirable side effects associated with administration of a racemic mixture of nitrendipine. A method is disclosed utilizing an optically pure isomer of nitrendipine for treating hypertension while reducing undesirable side effects associated with nitrendipine.
    Type: Grant
    Filed: March 13, 1990
    Date of Patent: March 2, 1993
    Assignee: Sepracor, Inc.
    Inventors: Timothy J. Barberich, James W. Young
  • Patent number: 5171582
    Abstract: This invention relates to a composition for use in the treatment of iodine deficiency diseases such as fibrocystic dysplasia of the breast, breast cancer, endometriosis and premenstrual syndrome. The composition may also be used for the prophylaxis of breast cancer. More particularly, this invention relates to a composition for the treatment of iodine deficiency diseases, the composition comprising a solution of elemental iodine (I.sub.2) which may also be referred to as metallic iodine or iodine metal. The elemental iodine is soluble in water which leaves it thermodynamically free. The term "aqueous iodine" may also be used to refer to such an aqueous solution.
    Type: Grant
    Filed: January 3, 1989
    Date of Patent: December 15, 1992
    Inventors: William R. Ghent, Bernard A. Eskin
  • Patent number: 5162313
    Abstract: The administration of tin protoporphyrin, tin mesoporphyrin or tin diiododeuteroporphyrin to mammals, notably humans, increases the rate at which heme is excreted by mammals, and is useful for treatment of body tissue injury associated with hemorrhage in the body.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: November 10, 1992
    Assignee: The Rockefeller University
    Inventors: Attallah Kappas, George S. Drummond
  • Patent number: 5156840
    Abstract: The invention relates to amine-containing porphyrin derivatives. Theporphyrins can be used as photosensitizers which are useful as therapeutic agents. Also described are methods for preparing conjugates in which a porphyrin derivative is covalently attached to an antibody or antibody fragment. In vivo therapeutic methods utilizing the conjugates are also desired.
    Type: Grant
    Filed: March 20, 1989
    Date of Patent: October 20, 1992
    Assignee: Cytogen Corporation
    Inventors: John W. F. Goers, Hurley D. King, Chyi Lee, Daniel J. Coughlin, Vernon L. Alvarez, John D. Rodwell, Thomas J. McKearn
  • Patent number: 5128329
    Abstract: Physically and chemically stable insecticidal preparation in the form of aqueous emulsion or suspension is provided wherein active ingredients which are oily or solid and hardly soluble or insoluble in water are mixed in water with nonionic surfactants having an HLB value of 11 or less and thickeners.
    Type: Grant
    Filed: June 2, 1989
    Date of Patent: July 7, 1992
    Assignees: Sumitomo Corporation, Yuko Chemical Industries, Co., Ltd.
    Inventors: Fumiyasu Minagawa, Toshiyuki Tange, Kazuyuki Maeda
  • Patent number: 5116873
    Abstract: Oral or parenteral administration of thyroid hormone T.sub.4 (from 0.5 to 2 .mu.g/100 g of body weight) stimulates, normalizes dopaminergic innervation in the corpus striatum (striate body), and restores neurochemical compensation following denervation of selective brain areas, thereby increasing neuronal plasticity.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: May 26, 1992
    Inventors: Alfredo Gorio, Enrico Genazzani
  • Patent number: 5116845
    Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: May 26, 1992
    Assignee: Bristol-Myers Company
    Inventors: Hiroaki Ohkuma, Masataka Konishi, Kiyoshi Matsumoto, Toshikazu Oki, Yutaka Hoshino
  • Patent number: 5112814
    Abstract: A method is provided for treating Parkinson's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/8 to 1/2 grams/kilogram bodyweight per day.
    Type: Grant
    Filed: October 24, 1990
    Date of Patent: May 12, 1992
    Inventor: Robert Sabin
  • Patent number: 5112856
    Abstract: Inflammatory bowel disease and other leukotriene-mediated inflammation of the intestinal mucosa are treated therapeutically by the oral, rectal or parenteral administration of racemic-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy]-3,4-d ihydro-2H-1-benzopyran-2-carboxylic acid, or a salt, lower alkyl ester or enantiomer thereof.
    Type: Grant
    Filed: August 16, 1990
    Date of Patent: May 12, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Timothy S. Gaginella, Ann F. Welton, Peter C. Will
  • Patent number: 5108991
    Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3, N is 6-11 and R is --CH.sub.3.
    Type: Grant
    Filed: December 31, 1985
    Date of Patent: April 28, 1992
    Assignee: Whitby Research, Inc.
    Inventor: Vithal J. Rajadhyaksha
  • Patent number: 5106877
    Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
    Type: Grant
    Filed: October 31, 1990
    Date of Patent: April 21, 1992
    Assignee: The Rockefeller University
    Inventors: Peter C. Ulrich, Anthony Cerami
  • Patent number: 5100919
    Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
    Type: Grant
    Filed: October 31, 1990
    Date of Patent: March 31, 1992
    Assignee: The Rockefeller University
    Inventors: Peter C. Ulrich, Anthony Cerami
  • Patent number: 5100916
    Abstract: A preparation for treatment of addiction to alcohol, containing a carbamic acid ester having the general formula I ##STR1## wherein X is --CH.sub.3 or --CH.sub.2 CH.sub.3, R and R.sub.1 which may be the same or different, are hydrogen, C.sub.1-5 alkyl or a group of the formula ##STR2## wherein n is 0, 1 or 2, and R.sub.2, R.sub.3 and R.sub.4 are H, OH, OCH.sub.3, CH.sub.3, NO.sub.2 or halogen, and wherein R and R.sub.1 together with the nitrogen atom can form a saturated ring system having 4-6 atoms selected among C, N, O or S, and wherein A is sulphur or oxygen.
    Type: Grant
    Filed: October 30, 1990
    Date of Patent: March 31, 1992
    Assignee: Bio-Tox Diagnostics Kommanditbolag
    Inventors: Benny Johansson, Erling Petersen, Elisabeth Arnold
  • Patent number: 5096707
    Abstract: A treatment regimen for cancers having cells which are susceptible to an interleukin-2 activated natural killer cell mediated anti-cancer effect, the method comprises administering to a patient an effective amount of a combination of interleukin 2 and flavone-8-acetic acid. The treatment regimen is particularly effective in the treatment of renal carcinoma. Synergistic pharmaceutical compositions are also provided. effective in the treatment of renal carcinoma. Synergistic pharmaceutical compositions are also provided.
    Type: Grant
    Filed: April 15, 1988
    Date of Patent: March 17, 1992
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Wiltrout, Ronald L. Hornung
  • Patent number: 5096921
    Abstract: .alpha.-[10-oxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene]-carboxyli c acids, or physiologically-hydrolysable and -acceptable esters or pharmaceutically acceptable salts thereof are useful for effecting monokine inhibition, in particular interleukin-1 release or secretion inhibition, as a therapeutic means other than anti-inflammatory or anti-pyretic means.
    Type: Grant
    Filed: August 2, 1990
    Date of Patent: March 17, 1992
    Assignee: Sandoz Ltd.
    Inventors: Pietro Bollinger, Hans U. Gubler, Jorg Schnyder
  • Patent number: 5096930
    Abstract: This invention relates to a treatment for the improvement of regeneration of injured striated muscles, the key-feature of which is the application of n-butylamine, in natural or ionic form or in buffered solution, as effective substance.
    Type: Grant
    Filed: November 15, 1989
    Date of Patent: March 17, 1992
    Assignee: Ceskoslovenska akademie ved
    Inventors: Jan Zenka, Dagmar Hulinska, Radim Holusa, Theodor Pokorny, Alexandr Jegorov
  • Patent number: 5096927
    Abstract: A method for treatment of a hepatobiliary disease which comprises administering, to a subject in need of such treatment, a 15-ketoprostaglandin compound in an amount effective in treatment of the hepatobiliary disease.
    Type: Grant
    Filed: October 19, 1990
    Date of Patent: March 17, 1992
    Assignee: K.K. Ueno Seiyaku Oyo Kenkyujo
    Inventors: Ryuji Ueno, Hiroyoshi Osama
  • Patent number: 5095037
    Abstract: A pharmaceutical composition for treating inflammatory diseases, comprising (A) an effective amount of hyaluronic acid or its salt, and (B) an effective amount of an anti-inflammatory agent. The composition exhibits a synergistic therapeutic effect on inflammations and is useful for treating inflammatory diseases, particularly diseases of joint with inflammation.
    Type: Grant
    Filed: December 6, 1990
    Date of Patent: March 10, 1992
    Assignee: Nissho Corporation
    Inventors: Kenichi Iwamitsu, Yukio Nakamura, Masahiro Kawasaki, Yoshio Fukui
  • Patent number: 5095033
    Abstract: A method for treating epilepsy in humans which comprises administering stiripentol to a patient under antiepileptic treatment with usual drugs in order to alleviate or prevent side effects. The invention also provides an antiepileptic composition comprising stiripentol.
    Type: Grant
    Filed: March 1, 1991
    Date of Patent: March 10, 1992
    Assignee: Laboratoires Biocodex
    Inventors: Rene H. Levy, Joan S. Lockard, Richard H. Finnell, Bernard M. Hublot, Jacques A. Tor
  • Patent number: 5093352
    Abstract: 2-aryl substituted N-acetyl tryptamines are utilized as antidepressant agents.
    Type: Grant
    Filed: May 16, 1990
    Date of Patent: March 3, 1992
    Assignee: Whitby Research, Inc.
    Inventor: Margarita L. Dubocovich